Solid Biosciences Llc Stock Performance
| SLDB Stock | USD 6.83 0.01 0.15% |
On a scale of 0 to 100, Solid Biosciences holds a performance score of 12. The entity has a beta of 3.13, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Solid Biosciences will likely underperform. Please check Solid Biosciences' sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to make a quick decision on whether Solid Biosciences' existing price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Solid Biosciences LLC are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental indicators, Solid Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.15) | Five Day Return (2.84) | Year To Date Return 75.13 | Ten Year Return (97.99) | All Time Return (97.99) |
Last Split Factor 1:15 | Last Split Date 2022-10-28 |
1 | Solid Biosciences to Participate at the Jefferies Global Healthcare Conference | 05/28/2025 |
2 | Disposition of 3079 shares by Jessie Hanrahan of Solid Biosciences at 3.96 subject to Rule 16b-3 | 05/29/2025 |
3 | Acquisition by Howton David T of 58750 shares of Solid Biosciences subject to Rule 16b-3 | 06/09/2025 |
4 | Acquisition by Sullivan Lynne Marie of 77500 shares of Solid Biosciences at 4.58 subject to Rule 16b-3 | 06/12/2025 |
5 | Acquisition by Nagendran Sukumar of 77500 shares of Solid Biosciences at 4.58 subject to Rule 16b-3 | 06/13/2025 |
6 | Sarepta Drops 42 percent on Fatalities Markets Eye Solid Biosciences | 06/18/2025 |
7 | Solid Biosciences Poised for Growth Amid Competitive Shifts SLDB Stock News | 06/26/2025 |
8 | Solid Biosciences Coverage Initiated by Analysts at Citigroup - MarketBeat | 06/30/2025 |
9 | Disposition of 4573 shares by Smith Ian F of Solid Biosciences subject to Rule 16b-3 | 07/03/2025 |
10 | Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Ta... | 07/08/2025 |
11 | Citi Initiates Coverage on Solid Biosciences Inc. with Buy Rating and 14 PT | 07/09/2025 |
12 | SHAREHOLDER NOTICE Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. and Encourages Long-Term SLDB Investors to Contact the Firm - P... | 07/10/2025 |
13 | Acquisition by Brooks Gabriel of 112900 shares of Solid Biosciences subject to Rule 16b-3 | 07/16/2025 |
14 | Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia | 07/23/2025 |
15 | Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 08/01/2025 |
| Begin Period Cash Flow | 75.8 M | |
| Total Cashflows From Investing Activities | -16.1 M |
Solid Biosciences Relative Risk vs. Return Landscape
If you would invest 423.00 in Solid Biosciences LLC on May 4, 2025 and sell it today you would earn a total of 260.00 from holding Solid Biosciences LLC or generate 61.47% return on investment over 90 days. Solid Biosciences LLC is currently generating 0.9768% in daily expected returns and assumes 6.409% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Solid, and 81% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Solid Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Solid Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Solid Biosciences LLC, and traders can use it to determine the average amount a Solid Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1524
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SLDB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.41 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.98 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 12 88% of assets perform better |
Based on monthly moving average Solid Biosciences is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Solid Biosciences by adding it to a well-diversified portfolio.
Solid Biosciences Fundamentals Growth
Solid Stock prices reflect investors' perceptions of the future prospects and financial health of Solid Biosciences, and Solid Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Solid Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 246.91 M | ||||
| Shares Outstanding | 77.52 M | ||||
| Price To Book | 1.80 X | ||||
| Price To Sales | 3.65 X | ||||
| Gross Profit | (108.47 M) | ||||
| EBITDA | (121.9 M) | ||||
| Net Income | (124.7 M) | ||||
| Cash And Equivalents | 162.88 M | ||||
| Cash Per Share | 1.44 X | ||||
| Total Debt | 24.18 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 7.85 X | ||||
| Book Value Per Share | 3.80 X | ||||
| Cash Flow From Operations | (100.01 M) | ||||
| Earnings Per Share | (3.01) X | ||||
| Market Capitalization | 530.21 M | ||||
| Total Asset | 188.66 M | ||||
| Retained Earnings | (783.45 M) | ||||
| Working Capital | 127.05 M | ||||
About Solid Biosciences Performance
By analyzing Solid Biosciences' fundamental ratios, stakeholders can gain valuable insights into Solid Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Solid Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Solid Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 33.64 | 29.90 | |
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (0.91) | (0.86) |
Things to note about Solid Biosciences LLC performance evaluation
Checking the ongoing alerts about Solid Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Solid Biosciences LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Solid Biosciences is way too risky over 90 days horizon | |
| Solid Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (124.7 M) with loss before overhead, payroll, taxes, and interest of (108.47 M). | |
| Solid Biosciences LLC currently holds about 162.88 M in cash with (100.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 |
- Analyzing Solid Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Solid Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Solid Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Solid Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Solid Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Solid Biosciences' stock. These opinions can provide insight into Solid Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Solid Stock analysis
When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |